Literature DB >> 26609342

Hepatocellular carcinoma: A comprehensive review.

Lisa P Waller1, Vrushak Deshpande1, Nikolaos Pyrsopoulos1.   

Abstract

Hepatocellular carcinoma (HCC) is rapidly becoming one of the most prevalent cancers worldwide. With a rising rate, it is a prominent source of mortality. Patients with advanced fibrosis, predominantly cirrhosis and hepatitis B are predisposed to developing HCC. Individuals with chronic hepatitis B and C infections are most commonly afflicted. Different therapeutic options, including liver resection, transplantation, systemic and local therapy, must be tailored to each patient. Liver transplantation offers leading results to achieve a cure. The Milan criteria is acknowledged as the model to classify the individuals that meet requirements to undergo transplantation. Mean survival remains suboptimal because of long waiting times and limited donor organ resources. Recent debates involve expansion of these criteria to create options for patients with HCC to increase overall survival.

Entities:  

Keywords:  Expansion Milan Criteria; Hepatectomy; Hepatocellular carcinoma; Liver transplantation; Living donor liver transplantation; Mammalian target of rapamycin inhibitors; Milan Criteria; Salvage liver transplantation; Sorafenib; Transarterial chemoembolization; University of California San Francisco Criteria

Year:  2015        PMID: 26609342      PMCID: PMC4651909          DOI: 10.4254/wjh.v7.i26.2648

Source DB:  PubMed          Journal:  World J Hepatol


  112 in total

1.  Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue.

Authors:  Andrea Mancuso; Chiara Mazzarelli; Giovanni Perricone; Claudio Zavaglia
Journal:  J Hepatol       Date:  2013-11-09       Impact factor: 25.083

2.  Living donor liver transplantation: the Asian perspective.

Authors:  Chao-Long Chen; Yu-Fan Cheng; Chun-Yen Yu; Hsin-You Ou; Leo Leung-Chit Tsang; Tung-Liang Huang; Tai-Yi Chen; Allan Concejero; Chih-Chi Wang; Shih-Ho Wang; Tsan-Shiun Lin; Yueh-Wei Liu; Chin-Hsiang Yang; Chee-Chien Yong; King-Wah Chiu; Bruno Jawan; Hock-Liew Eng; See Ching Chan; William Wei Sharr; Chung-Mau Lo; Sumihito Tamura; Yasuhiko Sugawara; Norihiro Kokudo; Kwang-Woong Lee; Nam-Joon Yi; Kyung-Suk Suh; Deok-Bog Moon; Sung-Gyu Lee; Chul-Soo Ahn; Shin Huang; Ki-Hun Kim; Tae-Yong Ha; Gi-Wong Song; Dong-Hwan Jung; Gil-Chun Park; Jung-Man Namkoong; Hyung-Woo Park; Yo-Han Park; Cheon-Soo Park; Kyw-Bo Sung; Gi-Young Ko; Dong-Il Gwon; Toskimi Kaido; Kohei Ogawa; Yasuhiro Fujimoto; Takashi Ito; Koji Toniyama; Akira Mori; Yasuhiro Ogura; Shinji Uemoto; Anthony Q Yap; Yu-Hung Lin; Chun-Yi Liu; Yuan-Cheng Chiang; Chih-Chi Lin; Milljae Shin; Jae-Won Joh; Catherine Kabiling; Tsung-Hui Hu; Sung-Hwa Kang; Bo-Hyun Jung; Young-Rok Choi
Journal:  Transplantation       Date:  2014-04-27       Impact factor: 4.939

3.  Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  J I Herrero; B Sangro; J Quiroga; F Pardo; M Herraiz; J A Cienfuegos; J Prieto
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

4.  [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation].

Authors:  Xiaofei Zhao; Shichun Lu; Menglong Wang; Jushan Wu; Dongdong Lin; Qingliang Guo; Wei Lai; Daobing Zeng; Chuanyun Li; Yuan Liu; Libo Sun; Dong Yan; Ning Li
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2014-04

5.  Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.

Authors:  Hashem B El-Serag; Jennifer R Kramer; G John Chen; Zhigang Duan; Peter A Richardson; Jessica A Davila
Journal:  Gut       Date:  2011-01-21       Impact factor: 23.059

Review 6.  Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate.

Authors:  Matteo Cescon; Alessandro Cucchetti; Matteo Ravaioli; Antonio Daniele Pinna
Journal:  J Hepatol       Date:  2012-10-04       Impact factor: 25.083

7.  [Expressions of TNF-alpha, IL-6, CRP, and MCP-1 in phlegm-damp constitution population detected by multiplexed Luminex assay].

Authors:  Lu-Yu Zheng; Ling-Ling Yang; Ling-Ru Li; Hui-Ru Jing; Ji Wang; Qian-Fei Wang; Qi Wang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2013-07

Review 8.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Inflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancer.

Authors:  Masahide Ikeguchi; Sho-Ichi Urushibara; Ryugo Shimoda; Manabu Yamamoto; Yoshihiko Maeta; Keigo Ashida
Journal:  World J Surg Oncol       Date:  2014-07-15       Impact factor: 2.754

View more
  66 in total

1.  Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging.

Authors:  Dong Ik Cha; Kyung Mi Jang; Seong Hyun Kim; Tae Wook Kang; Kyoung Doo Song
Journal:  Eur Radiol       Date:  2017-04-03       Impact factor: 5.315

Review 2.  Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology.

Authors:  Sukeshi Patel Arora; Gabor Liposits; Susan Caird; Richard F Dunne; Gordon Taylor Moffat; David Okonji; Maria Grazia Rodriquenz; Divyanshu Dua; Efrat Dotan
Journal:  J Geriatr Oncol       Date:  2019-11-06       Impact factor: 3.599

3.  Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells.

Authors:  Zhong-Dong Wang; Fan-Yong Qu; Yuan-Yuan Chen; Zhang-Shen Ran; Hai-Yan Liu; Hai-Dong Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2017 Jan.       Impact factor: 3.066

4.  Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1-7) and miRNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism.

Authors:  Brenda de Oliveira da Silva; Luciane Carla Alberici; Letícia Ferreira Ramos; Caio Mateus Silva; Marina Bonfogo da Silveira; Carlos R P Dechant; Scott L Friedman; Kumiko Koibuchi Sakane; Letícia Rocha Gonçalves; Karen C M Moraes
Journal:  Int J Biochem Cell Biol       Date:  2018-03-07       Impact factor: 5.085

5.  Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma.

Authors:  Kuo-Shyang Jeng; Chi-Juei Jeng; Wen-Juei Jeng; Chiung-Fang Chang; I-Shyan Sheen
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

6.  Long noncoding RNA uc.338 promotes cell proliferation through association with BMI1 in hepatocellular carcinoma.

Authors:  Changwen Bo; Na Li; Xiuli Li; Xianwei Liang; Yonghui An
Journal:  Hum Cell       Date:  2016-05-06       Impact factor: 4.174

Review 7.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

8.  Evaluation of Ferritin and Transferrin Ratio as a Prognostic Marker for Hepatocellular Carcinoma.

Authors:  Ishaan Vohra; Bashar Attar; Vatsala Katiyar; Pedro Palacios; Tejinder Randhawa; Muhammad Arslan Baig; Estefania Flores; Yuchen Wang; Hemant Mutneja; Sachit Sharma; Prashanth Lingamneni; Muhammad Zain Farooq; Naveen Bhaskaran; Seema Gandhi; Gijo Vettiankal; Melchor Demetria
Journal:  J Gastrointest Cancer       Date:  2021-03

Review 9.  Tumor thrombus: incidence, imaging, prognosis and treatment.

Authors:  Keith Bertram Quencer; Tamir Friedman; Rahul Sheth; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

10.  Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients.

Authors:  Xiaofeng Hang; Zhiqin Wu; Kaijian Chu; Guanzhen Yu; Haoran Peng; Haiguang Xin; Xiaohui Miao; Junxue Wang; Wensheng Xu
Journal:  Tumour Biol       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.